Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark
Table of Contents
- Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark
- FAQ
- What is dronabinol and how might it help COPD patients with severe breathlessness?
- Who are the ideal candidates for this dronabinol treatment approach?
- What does the treatment protocol involve for patients in this study?
- How is the effectiveness of dronabinol measured in treating breathlessness?
- What are the potential clinical implications if dronabinol proves effective for COPD breathlessness?
- Read next
- FAQ
Reducing severe breathlessness with dronabinol in the group of patients with severe and very severe chronic obstructive pulmonary disease (BONG): a randomised, double-blinded, placebo-controlled, crossover study in an outpatient clinic in Denmark
Randomized crossover trial will evaluate dronabinol for severe breathlessness in COPD patients with persistent symptoms despite optimal treatment.
This protocol describes a methodologically sound crossover design to evaluate cannabinoids for COPD-related breathlessness, addressing a significant unmet clinical need. The crossover design allows each patient to serve as their own control, potentially reducing variability in this heterogeneous patient population.
Severe COPD patients often experience persistent breathlessness despite optimal bronchodilator and anti-inflammatory therapy, leaving clinicians with limited options. Cannabis-based medicines represent a potential novel approach for this distressing symptom that significantly impacts quality of life.
| Study Type | Randomized Controlled Crossover Trial Protocol |
| Population | 30 adults with severe/very severe COPD and persistent breathlessness despite optimal treatment |
| Intervention | Dronabinol (synthetic THC) for 4 weeks |
| Comparator | Placebo for 4 weeks with 2-week washout between treatments |
| Primary Outcome | Breathing discomfort measured on 0-10 Numerical Rating Scale |
| Key Finding | Study protocol published – no results reported |
| Journal | BMJ Open |
| Year | 2024 |
This well-designed study protocol will provide needed evidence on whether synthetic THC can reduce breathlessness in severe COPD patients who remain symptomatic on standard care. The crossover design and validated outcome measures strengthen the potential clinical relevance of future results.
This is a protocol paper with no actual efficacy or safety data reported. The study has not yet been completed, so no conclusions about dronabinol’s effectiveness for COPD breathlessness can be drawn from this publication.
The small sample size of 30 patients may limit statistical power and generalizability. Blinding may be challenging given THC’s psychoactive effects, and the 4-week treatment periods may not capture long-term efficacy or tolerance development.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →This protocol represents thoughtful research design for evaluating cannabinoids in severe COPD, but provides no efficacy data. Clinicians should await study completion before considering any practice changes regarding cannabis-based treatments for COPD breathlessness.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is dronabinol and how might it help COPD patients with severe breathlessness?
Dronabinol is a synthetic form of THC (tetrahydrocannabinol), the active compound in cannabis. This study investigates whether dronabinol can reduce breathing discomfort in patients with severe COPD who continue to experience persistent breathlessness despite receiving optimal standard treatment.
Who are the ideal candidates for this dronabinol treatment approach?
The study targets patients aged 18 years and older with severe to very severe COPD who experience persistent breathlessness despite optimal medical management. Patients with ongoing infections, substance abuse history, or significant comorbidities are excluded from consideration.
What does the treatment protocol involve for patients in this study?
Patients receive either dronabinol or placebo for 4 weeks, followed by a 2-week washout period, then cross over to the alternative treatment for another 4 weeks. This crossover design allows each patient to serve as their own control, improving the reliability of results.
How is the effectiveness of dronabinol measured in treating breathlessness?
The primary outcome measures breathing discomfort using a 0-10 Numerical Rating Scale to assess the unpleasantness of breathlessness. Secondary outcomes include lung function tests, quality of life questionnaires, functional assessments, and plasma THC concentrations to evaluate comprehensive treatment effects.
What are the potential clinical implications if dronabinol proves effective for COPD breathlessness?
If successful, this could provide a new therapeutic option for the most severely affected COPD patients who have exhausted standard treatments. Given the study’s high clinical relevance rating, positive results could lead to expanded research and potential integration into clinical practice guidelines for managing refractory breathlessness in severe COPD.
